Education
About Us
Working with TipRanks
Follow Us
Processa Pharmaceuticals (PCSA)
NASDAQ:PCSA
Total Valuation
Processa Pharmaceuticals has a market cap or net worth of $15.29M. The enterprise value is -$3.72M.
Market Cap$15.29M
Enterprise Value-$3.72M
Share Statistics
Processa Pharmaceuticals has 56,644,222 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding56,644,222
Owned by Insiders1.22%
Owned by Institutions2.03%
Financial Efficiency
Processa Pharmaceuticals’s return on equity (ROE) is -6.99 and return on invested capital (ROIC) is -684.16%.
Return on Equity (ROE)-6.99
Return on Assets (ROA)-3.67
Return on Invested Capital (ROIC)-684.16%
Return on Capital Employed (ROCE)-7.10
Revenue Per Employee0.00
Profits Per Employee-1.19M
Employee Count10
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Processa Pharmaceuticals is ―. Processa Pharmaceuticals’s PEG ratio is 0.00420.
PE Ratio―
PS Ratio0.00
PB Ratio1.59
Price to Fair Value1.59
Price to FCF-0.24
Price to Operating Cash Flow>-0.01
PEG Ratio0.00420
Income Statement
In the last 12 months, Processa Pharmaceuticals had revenue of 0.00 and earned -11.85M in profits. Earnings per share was -3.87.
Revenue0.00
Gross Profit0.00
Operating Income-12.05M
Pretax Income-11.85M
Net Income-11.85M
EBITDA-12.05M
Earnings Per Share (EPS)-3.87
Cash Flow
In the last 12 months, operating cash flow was -10.73M and capital expenditures 0.00, giving a free cash flow of -10.73M billion.
Operating Cash Flow-10.73M
Free Cash Flow-10.73M
Free Cash Flow per Share-0.19
Dividends & Yields
Processa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.20
52-Week Price Change-74.04%
50-Day Moving Average0.31
200-Day Moving Average0.28
Relative Strength Index (RSI)46.61
Average Volume (3m)17.04M
Important Dates
Processa Pharmaceuticals upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Processa Pharmaceuticals as a current ratio of 1.22, with Debt / Equity ratio of 0.42%
Current Ratio1.22
Quick Ratio1.22
Debt to Market Cap0.00
Net Debt to EBITDA0.09
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Processa Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Processa Pharmaceuticals EV to EBITDA ratio is -0.13, with an EV/FCF ratio of -0.14.
EV to Sales0.00
EV to EBITDA-0.13
EV to Free Cash Flow-0.14
EV to Operating Cash Flow-0.14
Balance Sheet
Processa Pharmaceuticals has $6.31M in cash and marketable securities with $0.00 in debt, giving a net cash position of $6.31M billion.
Cash & Marketable Securities$6.31M
Total Debt$0.00
Net Cash$6.31M
Net Cash Per Share$0.11
Tangible Book Value Per Share$0.55
Margins
Gross margin is 22.53%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin22.53%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Processa Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast72.88%